Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

X
Trial Profile

A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NGM 707 (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Biliary cancer; Carcinoma; Cervical cancer; Colorectal cancer; Gastric cancer; Glioblastoma; Head and neck cancer; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors NGM Biopharmaceuticals
  • Most Recent Events

    • 29 Mar 2024 Results characterizing the pharmacokinetic (PK) and pharmacodynamic (PD) properties of NGM707 , presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 19 Mar 2024 According to a NGM Biopharmaceuticals media release, two abstracts highlighting clinical data from the ongoing Phase 1/2 clinical trial of NGM707, have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, CA.
    • 11 Mar 2024 According to a NGM Biopharmaceuticals media release, expects to complete enrollment in the Phase 1 Part 1b cohort in the second quarter of 2024 and anticipates providing an update in mid-2024 on the fully enrolled cohort and subsequent next steps, including, provided sufficient financial resources, the potential for additional cohorts, which NGM Bio expects will include MSS CRC patients.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top